期刊文献+

肠复康方对大肠癌细胞多药耐药的逆转作用机制研究 被引量:1

下载PDF
导出
摘要 目的:通过血清药理学(serum pharmacology)及分子生物学(molecular biology)原理探讨肠复康方对大肠多药耐药逆转机理。方法:采用蛋白质印迹法(Western Blot)的实验方法检测多药耐药相关蛋白(multidrug resistanceassociated protein) P-gp、LRP、MRP1及COX-2的表达。结果:肠复康方能够使相关蛋白P-gp、LRP、MRP1及COX-2的表达发生明显的下降,差异有统计学意义(P <0. 01)。结论:肠复康在相当程度上会促使P-gp、LRP、MRP1、COX-2的表达呈下调的趋势,考虑可能与大肠癌多药耐药的逆转机理有一定的联系。 Objective This study using the research methods of serum pharmacology and molecular biology to explore that the reversal effect of traditional Chinese medicine Changfukang for the multidrug resistance of clolrectal cancer,and its reversal mechanism,to provide research basis for its application in the clinical treatment of colorectal cancer. Methods Western blot method was used to detect the expression of colorectal cancer multidrug resistance-associated protein P-gp、MRP1、LRP and COX-2 to Changfukang.Results Changfukang can significant decrease the expression of resistance-associated protein p-gp、MRP1、LRP、and COX-2,the different was statistically significant( P < 0. 01). Conclusion The study showed that Chang Fu Kang can reduce the expression of colorectal cancer multidrug resistance protein P-gp、LRP、MRP1 and COX-2,It mainly reversed the mechanism of multidrug resistance of colorectal cancer.
作者 陈铭 钱海兵 CHEN Ming;QIAN Haibing(Guiyang University of ehinese Medieine,Guiyang 55002,China)
机构地区 贵阳中医学院
出处 《中国民族民间医药》 2018年第18期9-11,共3页 Chinese Journal of Ethnomedicine and Ethnopharmacy
关键词 肠复康方 大肠癌 多药耐药 逆转 ChangFuKang Prescription Colorectal Cancer MDR Reverision
  • 相关文献

参考文献4

二级参考文献28

  • 1孙燕 周际昌.临床肿瘤内科手册(第3版)[M].北京:人民卫生出版社,1997.53-54.
  • 2Ryu SH,Chung YH.How to overcome multidrug resistance in chemotherapy for advanced hepatocellular carcinoma.Liver Int,2010,30(4):585-592.
  • 3Johnson KA,Brown PH.Drug development for cancer chemoprevention:focus on molecular targets.Semin Oncol,2010,37 (4):345-358.
  • 4Tsukamoto Y,Kato Y,Ura M,et al.A physiologically based pharmacokinetic analysis of capecitabine,a triple prodrug of 5-FU,in humans:the mechanism for tumor-selective accumulation of 5-FU.Pharm Res,2001,18(8):1190-1202.
  • 5Lage H.An overview of cancer multidrug resistance:a still unsolved problem.Cell Mol Life Sci,2008,65 (20):3145-3167.
  • 6Wakamatsu T,Nakahashi Y,Hachimine D,et al.The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins.Int Oncol,2007,31 (6):1465-1472.
  • 7Vander Borght S,Komuta M,Libbrecht L,et al.Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin.Liver Int,2008,28 (10):1370-1380.
  • 8Kunnimalaiyaan M,Ndiaye M,Chen H.Apoptosis-mediated medul-lary thyroid cancer growth suppression by the PI3K inhibitorLY294002[J].Surgery,2010,140(6):1009-1014.
  • 9Westfall SD,Skinner MK.Inhibition of phosphatidylinositol 3-ki-nase sensitizes ovarian cancer cells to carboplatin and allows adjunctchemotherapy treatment[J].Molecular Cancer Therapentics,2008,4(11):1764-1771.
  • 10Lu B,Shioohar ET,Edwards E,et al.The use of tyrosine kinaseinhibitors in modifying the response of tumor microvasculature to ra-diotherapy[J].Technology in Cancer Research Treatment,2005,4(6):691-698.

共引文献36

同被引文献19

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部